Compare BNED & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNED | ZURA |
|---|---|---|
| Founded | 1965 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.9M | 455.4M |
| IPO Year | 2015 | 2021 |
| Metric | BNED | ZURA |
|---|---|---|
| Price | $12.46 | $0.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $17.25 | $8.00 |
| AVG Volume (30 Days) | 147.9K | ★ 6.7M |
| Earning Date | 12-08-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ 119.60 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,714,770,000.00 | N/A |
| Revenue This Year | $2.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.50 | N/A |
| 52 Week Low | $5.90 | $0.93 |
| 52 Week High | $14.75 | $7.25 |
| Indicator | BNED | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 24.55 |
| Support Level | $11.55 | N/A |
| Resistance Level | $13.11 | $5.97 |
| Average True Range (ATR) | 0.48 | 0.24 |
| MACD | -0.09 | -0.18 |
| Stochastic Oscillator | 21.10 | 0.02 |
Barnes & Noble Education Inc is contract operators of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States. The company is also one of the textbook wholesalers and inventory management hardware and software providers The company operates physical and virtual bookstores that delivers essential educational content and general merchandise within a dynamic omnichannel retail environment. The Company currently operates as a single operating and reporting segment. The company's solutions are Academic Solutions, College Retail Solutions, College Insights, Wholesale & Store Technology Services.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.